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Transient gene expression (TGE) is the most commonly
used technology for the rapid production of moderate
quantities of recombinant proteins for preclinical studies
or for analytical assay development [1,2]. Whereas TGE
can provide milligram to gram amounts of recombinant
proteins within a time period as short as few days, tech-
nical limitations and high costs of plasmid DNA hamper
the application of this technology at larger scales. Here
we describe an alternative method for the fast produc-
tion of recombinant proteins from pools of mammalian
cells stably transfected with the PiggyBac (PB) transpo-
son. Expression from stably integrated transgene is
highly dependent upon the chromatin structure sur-
rounding the site of integration [3]. As a consequence
stable cell populations generated by conventional trans-
fection techniques generally show low productivity and
reduced expression stability. Several studies showed that
the PB transposase mediated transgene insertion predo-
minantly into actively transcribed regions of the mam-
malian genome [4,5], moreover we recently
demonstrated that PB transposition generates high-pro-
ducing CHO cell lines at a higher frequency than con-
ventional plasmid transfection [6]. These results
prompted us to develop a technology based on the use
of stable pools generated by PB transposition for the
rapid and scalable production of recombinant proteins.
Initial experiments were aimed at determining the
proportion of transgene expressing cells as well as the
level and stability of recombinant protein production in
PB transposed pools. First, we analyzed transgene
expression in 952 cell lines recovered from a pool of
CHO cells generated by PB-transposition to express
tumor necrosis factor receptor as an Fc fusion protein
(TNFR:Fc). The cell lines were analyzed by ELISA for
TNFR:Fc expression in 4-day batch cultures. The clones
showed levels of TNFR:Fc expression up to 360 mg/L
with an overall mean of 96 +/- 54 mg/L. PB-transposi-
tion resulted in a high percentage (more than 98%) of
TNFR:Fc expressing clones (data not shown). Analyses
on the stability of transgene expression over time were
conducted using a bicistronic PB-donor plasmid allow-
ing co-expression of TNFR:Fc and the enhanced green
fluorescent protein (eGFP). Five independent pools of
cells were generated by transposition and recovered
after 10 days of selection in puromycin. The pools were
cultivated for 3 months in the absence of selection and
eGFP expression was monitored periodically by flow
cytometry. For each pool, the percentage of eGFP-posi-
tive cells remained stable over time (Table 1). The stabi-
lity of transgene expression was further confirmed by
TNFR:Fc productivity studies performed in 50-ml cul-
tures at different time points post-transfection. At one
month post-transfection, the five pools showed compar-
able growth and production characteristics, reaching
TNFR:Fc titers in the range of 350-500 mg/L in 14-day
batch cultures. Similar results were obtained when pro-
ductivity was tested 2 – 3 months post-transfection
(Table 1).
We developed a protocol for protein production from
transposed cell pools at the 0.5-L scale (Figure 1A).
Starting at 2 d post-transfection cells were subjected to
10 days of puromycin selection during which cells were
expanded from TubeSpin
® Bioreactor 50 tubes into
orbitally shaken 250-mL cylindrical bottles. The batch
bioprocess was finally starteda t1 2dp o s t - t r a n s f e c t i o n
using orbitally shaken TubeSpin
® Bioreactor 600 tubes.
Using stable cell pools expressing either an IgG antibody
(Fig. 1B) or two TNFR:Fc variants (Fig. 1C, D), we pro-
duced 500-750 mg of recombinant protein within a
month after transfection.
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any medium, provided the original work is properly cited.Table 1 Analysis of the stability or recombinant protein expression in 5 independent pools of CHO cells.
CHO-Pool Days post transfection % eGFP positive cells
(*) TNFR:Fc productivity (mg/L)
(°)
30 92.8 ± 2.1 430 ± 46
1 60 93.3 ± 0.2 455 ±10
90 92.5 ± 1.2 473 ± 10
30 90.0 ± 0.8 348 ± 36
2 60 91.4 ± 0.5 370 ± 8
90 94.0 ± 1.1 325 ± 35
30 94.0 ± 1.5 432 ± 25
3 60 94.2 ± 1.1 451 ± 28
90 91.9 ± 1.8 494 ± 16
30 92.0 ± 0.2 432 ± 30
4 60 90.1 ± 2.0 407 ± 23
90 92.3 ± 1.3 406 ± 28
30 96.1 ± 1.5 388 ± 52
5 60 92.4 ± 1.4 466 ± 19
90 93.6 ± 0.2 372 ± 12
(*) determined by GUAVA flow cytometry; (°) determined by ELISA.
Figure 1 (A) Schematic representation of the protocol for the rapid production of recombinant proteins from pools of transposed cells. This
protocol was successfully used to produce a recombinant monoclonal antibody (B) and two variants of TNFR:Fc (C and D). For each bioprocess
shown, the percentage of viable cells (dotted lines) the viable cell density (dashed lines), and the recombinant protein titer (solid lines) were
measured at the times indicated
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lity of transgene expression in transposed pools, indicat-
ing usefulness of PB transposed cell pools as a valuable
alternative to TGE for the rapid production of recombi-
nant proteins.
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